- Home
- GLO vs ATAI Comparison
GLO vs ATAI Comparison
Compare GLO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLO | ATAI |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.8M | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GLO | ATAI |
|---|---|---|
| Price | $5.90 | $4.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.86 |
| AVG Volume (30 Days) | 170.5K | ★ 3.9M |
| Earning Date | 01-01-0001 | 03-16-2026 |
| Dividend Yield | ★ 11.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,018,000.00 |
| Revenue This Year | N/A | $962.66 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $4.08 | $1.15 |
| 52 Week High | $5.18 | $6.75 |
Technical Indicators
Market Signals| Indicator | GLO | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 57.09 |
| Support Level | $5.82 | $3.50 |
| Resistance Level | $6.09 | $3.85 |
| Average True Range (ATR) | 0.06 | 0.22 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 51.32 | 99.34 |
Price Performance
Historical ComparisonAbout GLO Clough Global Opportunities Fund
Clough Global Opportunities Fund is a closed-end management investment company based in the United States. Its investment objective is to provide a high level of total return by investing in equity securities of companies of any market capitalization and equity-related securities, including equity swaps and call options, as well as fixed-income securities, including both corporate and sovereign debt, in both U.S. and non-U.S. markets.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.